Drug maker Lupin today said it has received approval from the US health regulator to market its Suprax capsules, used for treating bacterial infections, in the American market.
The company's subsidiary, Lupin Pharmaceuticals Inc, has received new drug application (NDA) approval from the United States Food and Drug Administration (USFDA) for Suprax (Cefixime) capsules in the strength of 400 mg, Lupin said in a statement.
The firm expects to commence shipping the product in the near future, it added.
Commenting on the development, Lupin Group President & ED Nilesh Gupta said: "The new dosage form will add to our growing Suprax franchise and gives healthcare providers and patients a new formulation to treat the indicated infections".
The approval will expand Lupin's range of Suprax dosage forms. The product is currently available as 100 mg/5ml, 200 mg/5ml suspensions and 400 mg tablets, the statement said.
Shares of Lupin Ltd were being quoted at Rs 537 in the afternoon trade on the BSE today, up 0.74 per cent from previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app